Background: Lymphocytosis and smudge cells are commonly observed on the blood smears of patients with an established or suspected diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma. Excluding smudge cells from the manual differential count (MDIFF), a common laboratory practice, yields unreliable results and consequently necessitates performing the MDIFF testing on an albuminized blood smear.
performed on albuminized blood smear whenever the initial nonalbuminized smear reveals many smudge cells. 3 The process of albuminization of blood and performing MDIFF on the albuminized smear after examining the initial nonalbuminized smear under the microscope apparently requires extra time and effort. In an attempt to find a simple and practical solution for this process, it was previously shown in a report by 2 of us 7 that automated differential leukocyte counts (ADIFFs) generated by the Sysmex hematology analyzers (XE-2100 and XE-5000, in particular; Sysmex Corporation) can be reported in place of MDIFFs performed on albuminized smears in patients diagnosed with or suspected of having CLL/SLL. However, over time, we have observed that Sysmex hematology analyzers (XE-2100 and XE-5000, in particular) do not always generate reportable ADIFF results on blood specimens drawn from patients with CLL/SLL.
In our laboratory, the Sysmex XE-5000 does not generate reportable ADIFFs on approximately 25% of the specimens drawn from patients known to have or suspected to have CLL/ SLL. Consequently, these specimens require MDIFF on an albuminized blood smear. A nonreportable ADIFF result from a Sysmex analyzer is an incomplete ADIFF result, which does not provide the percentage and absolute numbers of neutrophils, lymphocytes, and monocytes. In other words, it includes only the percentage and absolute numbers of eosinophils and basophils. It is now widely acknowledged that smudge cells in CLL/SLL represent remnants of fragile lymphoid cells. It is also acknowledged that the results of the routinely performed MDIFF test on the original nonalbuminized smear are inaccurate because the smudge cells are excluded from counting in the MDIFF process. 2, 3 The aims of our study were to assess the reliability of counting smudge cells as lymphocytes in the MDIFF on the original nonalbuminized blood smear and to determine how often and when the ADIFF results are also acceptable in this patient population.
Methods and Materials
During a period of approximately 19 months between May 2013 and November 2015 in our clinical laboratory, we collected, from the routine workload of approximately 700 specimens a day (400 complete blood counts [CBCs] with DIFF and 300 CBCs without DIFF), CBC and DIFF data on a total of 100 EDTA-anticoagulated blood specimens drawn from 80 patients. In total, 49 of these patients (61.2%) were newly diagnosed with CLL/SLL by immunophenotyping with flow cytometry and 31 patients (38.8%) were suspected of having CLL/SLL based on the results of a blood smear review by a pathologist. None were diagnosed with or suspected of having monoclonal B lymphocytosis because the lowest absolute lymphocyte count in the study population was 5.6 Â 10 3 per lL, from the blood specimen with the WBC count of 7.9 Â 10 3 per lL. Twenty of the 100 blood specimens represented repeat specimens drawn at an interval of 1 day to 590 days (mean, 89 days; median, 3 days) from 14 patients who had not yet opted for or received any therapy. CBC and the ADIFF data were generated on the Sysmex XE-5000 hematology analyzer, which was calibrated and quality controlled according to manufacturer recommendations. 8 The MDIFF data were obtained by performing a 100-cell (if the WBC count was < 20 Â 10 The MDIFFS for all of the study specimens were performed by one of the authors (G.G.). All smears were reviewed by a pathologist because of the presence of absolute lymphocytosis with or without morphologic abnormalities. The smears were prepared and stained using Romanowsky stain (Wright stain [per protocol from Thermo Fisher Scientific Inc]) using an SP-1000 automated smear maker and stainer (Sysmex Corporation). We counted smudge cells present in the nonalbuminized blood smears as lymphocytes in the MDIFF counting process. The albuminized blood smears showed, as expected, no or rare smudge cells; the latter, if present, were excluded from the MDIFF counting process because they represented an insignificant number.
For comparison of the differential (DIFF) results, we focused on 2 classes of WBCs, namely lymphocytes and neutrophils (including bands, if present) because these 2 cell types represented more than 90% of all WBCs in greater than 97% of the specimens. Although morphologically normalappearing lymphocytes and abnormal-appearing lymphoid cells were combined into the lymphocyte category for the purpose of comparison, we made a separate notation of the number and type of abnormal-appearing lymphoid cells if and when present in the smear. Prolymphocytes, activated lymphocytes, blasts, blast-like cells, and other unclassifiable abnormal-/immature-appearing lymphoid cells comprised the group of abnormal-appearing lymphoid cells, which are hereinafter referred to as other lymphoid cells. Individual cells in this group of other lymphoid cells were identified based on previously published morphologic criteria. 9 To confirm our previously reported finding that ADIFF results are also reliable in this patient population, we compared the results of available ADIFF tests with the available corresponding results of MDIFFs performed on nonalbuminized blood smears and albuminized blood smears. Microsoft Excel software (Microsoft Corporation) was used to calculate the mean and correlation coefficient (r 2 value) by linear regression for each cell population in each comparison group.
Results
The demographics of the 100 specimens from 80 patients included in the study are given in Table 1 . Among the patients, the male to female ratio was 1. /lL). The lymphocyte population, which included normal-/matureappearing lymphocytes and other lymphoid cells, if present, accounted for 34% to 100% (mean, 83%; median, 88%) of all WBCs by the predicate method (MDIFF performed on the albuminized blood smear). The neutrophil population accounted for 0% to 58% (mean, 13.6%; median, 10%) of all WBCs by the predicate method. We included a relatively low fraction of bands (in the range of 1% to 8% of all WBCs, with a mean of 5% and median of 2%) observed in approximately one-third of the specimens in the neutrophil counts. The smudge cells in the nonalbuminized blood smears graded according to the previously published criteria 10 ranged from 1þ to 4þ.
Corresponding MDIFF results between the albuminized blood smears and nonalbuminized blood smears were available for 82 of the 100 specimens. Albuminized blood smears were not prepared on 18 specimens because their nonalbuminized smears revealed 1þ smudge cells, and their ADIFF results were considered reportable according to the pre-established policy of our laboratory, based on previously reported findings. 7 The WBC counts of these 18 specimens ranged from 8. Table 2 ). The mean relative neutrophil count for the nonalbuminized smears was 14.0%, compared with 13.6% for the albuminized smears ( Table 2) . Linear regression analysis of the comparative data ( Figure 1 ) yielded an r 2 value of 0.92 for percentage (%) of lymphocytes and 0.94 for % neutrophils. Other lymphoid cells were noted in the albuminized blood smears and in the nonalbuminized blood smears of 25 of the 82 total specimens ( Table 3) . The mean relative other lymphoid cell count was 3.9% for the nonalbuminized blood smears and 6.8% for the albuminized blood smears. The relative fraction of the other lymphoid cells ranged from 1% to 10% of all WBCs in 24 of 25 nonalbuminized blood smears from 22 patients and in 22 of 25 albuminized blood smears from 22 patients. One of 25 nonalbuminized blood smears revealed 20% other lymphoid cells, and 3 of 25 albuminized blood smears revealed other lymphoid cells, at 11%, 15%, and 40% of all WBCs, respectively. There were 3 specimens for which the nonalbuminized blood smears did not reveal any other lymphoid cells, although their albuminized blood smears revealed 8% to 10% other lymphoid cells. Similarly, there were 3 different specimens for which the albuminized blood smears did not reveal any other lymphoid cells but the nonalbuminized blood smears revealed 1% to 4% other lymphoid cells.
Reportable ADIFFs were generated by the analyzer on 68 of 93 blood specimens (73.1%) processed for CBC with DIFF testing. Seven blood specimens had only a CBC ordered by the physician, and no discrete testing or any form of DIFF testing was performed on these specimens. A total of 59 of the 68 blood specimens (86.8%) with reportable ADIFF results were flagged by the analyzer for verification of the results by other means (ie, blood smear review and/or MDIFF testing [ Table 4 
]).
Among the flags generated by the analyzer, suspect nucleated red blood cells (NRBCs) with or without accompanied additional flags topped the list, with 44 specimens; followed by abnormal lymphocytes/lymphoblasts with or without accompanied additional flags, with 33 specimens; and other flags, individually or in various combinations, with 1 to 4 specimens each. No flags were generated by the analyzer on ADIFFs of 9 of 68 blood specimens (13.2%). Based on smear review, however, none of the 44 NRBC flags was considered a true flag, with ! 1 NRBC per 100 WBCs; none of the 9 immature granulocyte (IG) flags was considered a true flag, with ! 2% immature granulocytes; 2 of 7 left shift (LS) flags were considered true, with ! 5% bands; 6 of 9 blast flags were considered true, with ! 2% other lymphoid cells The mean relative neutrophil count for the ADIFFs was 20.0%, compared with 19.7% for the MDIFFs performed on the nonalbuminized blood smears ( Table 2) . Linear regression analysis of the comparative data between the ADIFF and the MDIFF results on the nonalbuminized blood smears (Figure 2 ) yielded r 2 ¼ 0.94 for lymphocytes and r 2 ¼ 0.97 for neutrophils.
Corresponding ADIFF and MDIFF results performed on the albuminized blood smears were available for 50 of 100 specimens. The analyzer did not generate reportable ADIFF results on 25 specimens, and ADIFF was not performed on 7 specimens because only a CBC without DIFF was ordered by the treating physician. Albuminized blood smears were not prepared on 18 specimens because their nonalbuminized smears revealed 1þ smudge cells, and their ADIFF results were considered reportable according to the pre-established policy of our laboratory, based on previously reported findings. 7 The mean relative lymphocyte count for the ADIFFs was 76.1%, compared with 79.2% for the MDIFFs performed on the albuminized blood smears ( Table 2 ). The mean relative neutrophil count for the ADIFFs was 18.7%, compared with 17.4% for the MDIFFs performed on the albuminized blood smears ( Table 2) . Linear regression analysis 
Discussion
Comparative data analysis of MDIFFs performed on nonalbuminized vs albuminized blood smears yielded identical means for the relative lymphocyte counts and a difference of only 0.4 percentage points for the means of relative neutrophil counts. We consider this difference in the mean relative neutrophil counts to be clinically insignificant.
Linear regression analysis of the corresponding MDIFF data between the 2 groups of smears revealed excellent correlation, with an r 2 value of 0.92 for the lymphoid population and 0.94 for the neutrophil population. The fraction and the types of other lymphoid cells (including prolymphocytes with or without other immature lymphoid cells), noted on 25 of 82 albuminized and nonalbuminized blood smears, did not reach a clinically significant level of over 10% (a level that could imply disease progression or transformation) in all but 1 nonalbuminized blood smear and 3 albuminized blood smears. This finding could imply disease progression or transformation in all but 1 nonalbuminized blood smear and 3 albuminized blood smears. One nonalbuminized blood smear revealed 20% Based on published literature on reproducibility of the manual differential (MDIFF) results, 13 only case numbers 5, 6, and 18 reveal statistically discordant results between the nonalbuminized and albuminized blood smears, and we consider only cases 6 and 18 to be clinically significant. The differences in the results of case numbers 9, 23, and 27, although they appear large, are neither statistically discordant nor clinically significant. Based on the recommended workflow algorithm ( Table 5 ), only case 6 will merit MDIFF testing on albuminized blood smear; others do not merit this testing unless clinically indicated. other lymphoid cells (4% prolymphocytes and 16% activated lymphocytes), whereas its albuminized counterpart revealed 11% other lymphoid cells (8% prolymphocytes and 3% activated lymphocytes). Among the remaining 2 albuminized blood smears with greater than 10% other lymphoid cells, 1 revealed 15% prolymphocytes, whereas its nonalbuminized counterpart revealed 10% prolymphocytes. The other albuminized blood smear revealed 40% prolymphocytes, whereas its nonalbuminized counterpart revealed 4% prolymphocytes.
These differences in number and type of other lymphoid cells between the 2 sets of smears in 3 of the 4 cases most likely reflect the variability anticipated with the morphologic assessment. An unexpectedly large difference in the number of prolymphocytes in 1 case, in which the albuminized blood smear revealed 40% prolymphocytes, compared with 4% in the nonalbuminized blood smear (as confirmed by pathologist review), remains unexplained. We can only speculate that either the albuminized and non-albuminized smears were not from the same patient (a laboratory error) or many of the prolymphocytes were fragile and got smudged in the non-albuminized blood smear.
Comparative analysis of ADIFF results with corresponding MDIFF results from nonalbuminized blood smears revealed excellent correlation by way of a difference of only 1.9 percentage points between the means of the relative lymphocytes counts, a difference of only 0.3 percentage points between the means of the relative neutrophil counts, and an r 2 value of 0.94 for the lymphoid population and 0.97
for the neutrophil population. Similarly, comparative analysis of ADIFF results with corresponding MDIFF results from albuminized blood smears also revealed excellent correlation by way of a difference of only 3.1 percentage points between the means of the relative lymphocytes counts, a difference of only 1.3 percentage points between the means of the relative neutrophil counts, and an r 2 value of 0.88 for the lymphoid population and 0.92 for the neutrophil population.
These observations provide additional evidence in support of a previously reported finding by 2 of us that ADIFF results from the Sysmex hematology analyzers (XE-5000, in particular), if and when available, can substitute for the MDIFF results obtained from the albuminized blood smears. A finding also revealed by the current study is that ADIFF results carrying the suspect NRBC flag are essentially reliable and consequently reportable. The ADIFF results carrying flags other than the suspect NRBC flag may be reliable more often than not if the flag is for abnormal lymphocytes/lymphoblasts, in particular. The same statement cannot be made at this time, however, for ADIFF results carrying other flags because of small number of specimens with such individual flags in our study population. Additional studies on much larger number of specimens in the future may be able to validate and further extend the reliability of the ADIFF results to include flags other than the suspect NRBC flag. Whether these findings can be applied to other models of Sysmex analyzers or analyzers from other manufacturers cannot be ascertained without performing comparison studies.
Also, a review of the results of the relative fraction of monocytes in individual cases (data not shown) revealed that all reportable ADIFFs, whether flagged or not, matched well with the corresponding MDIFFs performed on nonalbuminized and albuminized blood smears in all but 5 cases. The relative monocyte fraction of each of these 5 cases by ADIFF testing was !8% (range, 8% to 16%), compared with 0% to 3% by MDIFF on both sets of smears. 
ADIFF, automated differential count. Apparently, some of the other lymphoid cells, especially those that are large in size and thereby may mimic monocytoid cells, are counted as monocytes by the analyzer. Based on this new observation, we suggest that MDIFF testing be performed on a nonalbuminized blood smear whenever the relative fraction of monocytes by ADIFF is !8% in this patient population (ie, in the context of absolute lymphocytosis). From a practical standpoint, this procedure may be followed at the discretion of individual laboratories by defining a specific reflex rule for automated preparation of a blood smear in such cases.
Our study findings clearly indicate that a reliable MDIFF result can be obtained from the original nonalbuminized blood smear by counting smudge cells as lymphocytes. Our conclusions and recommendations on the optimal approach to reporting DIFF results on specimens from patients diagnosed with or suspected of having CLL/SLL, as outlined in Our data on the presence of other lymphoid cells in some cases do, however, suggest the need for performing MDIFF on the albuminized blood smear in a few select cases. The potential criteria for the select cases needing MDIFF on albuminized blood smear may include clinical indication of disease progression, transformation, and/or whether the fraction of other lymphoid cells exceeds 10%. The lattermost finding may be considered a laboratory indication for possible disease progression or transformation to chronic lymphocytic leukemia in prolymphocytic transformation (with prolymphocytes in the range of 11% to 50% of all WBCs), prolymphocytic leukemia (with prolymphocytes comprising >50% of all WBCs), or Richter syndrome (with development of diffuse large B-cell lymphoma or classical Hodgkin lymphoma).
Based on the current observations and the previously published findings, we have developed an algorithm (Table 5) for laboratory professionals to follow when reporting DIFF results for patients suspected of having or known to have CLL/SLL. In everyday practice, this algorithm can be applied to all specimens, initial and follow-up, that reveal absolute lymphocytosis (>5.0 Â 10 3 /lL in an adult) and/or !2þ (>20% of all white cells) smudge cells in the peripheral blood smear.
If we apply this algorithm to our study population of 100 specimens, 19 will have ADIFF results reported, 80 will have MDIFF results on nonalbuminized blood smear reported, and only 1 specimen (case 6 in Table 3 lymphoid cells (16% activated lymphocytes and 4% prolymphocytes) on MDIFF performed on nonalbuminized blood smear will get a MDIFF obtained an albuminized blood smear reported. The albuminized blood smear in this case revealed 3% activated lymphocytes and 8% prolymphocytes. In our opinion, these findings show a significant reduction from 100 MDIFFs on albuminized blood smears, if no algorithm is used, to only 1 MDIFF on albuminized blood smear, with 80 MDIFFs on nonalbuminized blood smears and 19 ADIFFs if the recommended algorithm ( Table 5 ) is followed.
Because we did not keep record of the total number of such specimens processed during the study period or for any period in our laboratory, we can neither calculate nor estimate associated annual cost savings. The extra time spent towards performing MDIFF testing on albuminized blood smear is approximately a few minutes per specimen, and the amount of associated annual cost savings will depend on the volume of specimens from patients with CLL/SLL (new and follow-up) that are routinely processed by individual laboratories. We emphasize that the algorithm, which is detailed in Table 5 , was developed solely to guide laboratory professionals in their decision to optimize the process of performing and reporting DIFF results on blood specimens from patients with established (old) or suspected (new) diagnosis of CLL/SLL. We hope that our algorithm and research findings will prove helpful to current and future healthcare professionals in choosing the most appropriate testing methods for specimens from their patients. LM
